Patents by Inventor Eva Guinan

Eva Guinan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9884089
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: February 6, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Publication number: 20170354712
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 14, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Patent number: 9770484
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: September 26, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Patent number: 9770483
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: September 26, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Publication number: 20170065676
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Application
    Filed: June 1, 2016
    Publication date: March 9, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Publication number: 20170056471
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Application
    Filed: June 1, 2016
    Publication date: March 2, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Publication number: 20140142024
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Application
    Filed: April 5, 2012
    Publication date: May 22, 2014
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Eva Guinan, Ofer Levy
  • Publication number: 20120238460
    Abstract: Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level.
    Type: Application
    Filed: November 10, 2008
    Publication date: September 20, 2012
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofer Levy, Eva Guinan, Eugenie Suter